- Mylan to launch educational site about generic drugs
- Let me tell you what PBMs do
- PhRMA: Nearly 300 preventive medicines for heart disease, stroke in development
- NACDS expresses position on two drug safety bills
- NACDS, NCPA urge rejection of administration's Tricare plan in favor of more 'balanced' alternatives
PARIS — A court in France has ordered generic drug maker Mylan to pay French drug maker Ipsen $24 million for allegedly misleading marketing of a drug, according to published reports.
Bloomberg reported that Mylan had allegedly marketed the drug Vitalogink as a generic version of Ipsen’s Tanakan rather than as a “therapeutic equivalent.” Both drugs are derived from ginkgo biloba and are used to improve memory.
Mylan has said it will appeal the decision, Bloomberg reported.